UBS/CALL/IDORSIA/2.505/0.2/21.03.25 Stock

UBS/CALL/IDORSIA/2.505/0.2/21.03.25 Share Price

Warrant

UFBS7U

CH1351208991

Market Closed - Swiss Exchange 08:50:00 17/06/2024 pm IST
0.2 ^CHF	-4.76%

Current month

-28.57%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/2.505/0.2/21.03.25

Latest news about IDORSIA LTD

Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds	28/06	GL
Swiss Cantonal Court Approves Amendments to Idorsia's Convertible Bonds	26/06	MT
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds	25/06	GL
Carmat: changes in corporate governance	25/06	CF

More news

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	UFBS7U
ISIN	CH1351208991
Date issued	21/05/2024
Strike	2.505 CHF
Maturity	21/03/2025 (265 Days)
Parity	5 : 1
Emission price	0.23 CHF
Emission volume	N/A
Settlement	physique
Currency	CHF

Technical Indicators

Highest since issue	0.29 CHF
Lowest since issue	0.2 CHF
Delta	0.71x
Omega	1.510
Premium	71.89x
Gearing	2.12x
Moneyness	0.8024
Difference Strike	0.479 CHF
Difference Strike %	+19.12%
Spread	0.02 CHF
Spread %	10.00%
Theoretical value	0.1900
Implied Volatility	166.52 %
Total Loss Probability	80.45 %
Intrinsic value	0.000000
Present value	0.1900
Break even	3.455 CHF
Theta	-0x
Vega	0x
Rho	0x

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company